Introduction. Fixed combinations of antiglaucoma drugs can optimize and simultaneously enhance the hypotensive effect of eye drops, and the most pathogenetically justified combination is the combination of a β-blocker and an inhibitor of carbonic anhydrase.

 

Aim of the study. To study the efficacy and local tolerance of the combined antiglaucoma drug Dorzitim® (2% dorzolamide hydrochloridi + 0.5% timolol maleate) in the treatment of patients with glaucoma.

 

Materials and methods. The study included 45 patients (90 eyes) with a newly diagnosed openangle glaucoma of the 2nd and 3rd stages. Patients with stage II of glaucoma with intraocular pressure (IOP) up to 25 mm Hg were treated with travoprost in monotherapy, and with greater IOP, – with Dorzitim®. Аll patients with stage III of glaucoma were prescribed a combination – travoprost and Dorzitim®. Accounting for IOP was carried out after 1 month.

 

Results and discussion. In the Dorzitim® group, there was a significant decrease in pressure from 28.45±2.0 mm Hg to 21.05±1.41 mm Hg (p-value <0.05, 38 eyes), an average of 26.42%, and in the group of using travoprost in combination with Dorsitim® the pressure decreased to 21.09±1.13 mm Hg a month after the start of treatment (p-value <0.05, 34 eyes), the average decrease was 28.58%.

 

Conclusion. Dorzitim® is an effective and safe drug for the treatment of glaucoma in monotherapy and in combination with travoprost.

 

Keywords: Dorzitim®, drug, monotherapy, travoprost, intraocular pressure, open-angle glaucoma.